Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy
in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may …

Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …

The integration of cancer biomarkers into oncology has revolutionized cancer treatment,
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …

In cancer patients, dendritic cells (DCs) in tumor-draining lymph nodes can present antigens
to naive T cells in ways that break immunological tolerance. The clonally expanded progeny …

B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific
neoantigens hold promise for providing long-term clinical benefit to patients with cancer …